{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002526","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.770715+00:00","generated_at":"2026-06-27T02:57:00.640680+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed","bullets":["Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.","Q4 2021 revenue $19.7M (up from $16.4M in Q4 2020); FY 2021 revenue $69.6M (down from $100.4M).","CX-2029 Phase 2 in sqNSCLC: 18.8% objective response rate, 87.5% disease control rate; safety consistent.","CX-904 (EGFRxCD3 TCB) IND allowed; Phase 1 in advanced solid tumors to start H1 2022.","Praluzatamab ravtansine Phase 2 in breast cancer: initial data for Arms A & B expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002526","json":"https://secwatch.observer/filing/0000950170-22-002526.json","markdown":"https://secwatch.observer/filing/0000950170-22-002526.md","text":"https://secwatch.observer/filing/0000950170-22-002526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/0000950170-22-002526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/ctmx-20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:57:00.640680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}